Today: 9 June 2026
Browse Category

NASDAQ:INSM 13 August 2025 - 2 January 2026

Liquidia stock drops 8% today as put-option hedging spikes — what’s next for LQDANEW YORK, Jan 2, 2026, 14:24 ET — Regular session

Liquidia stock drops 8% today as put-option hedging spikes — what’s next for LQDANEW YORK, Jan 2, 2026, 14:24 ET — Regular session

Liquidia shares fell about 8% Friday, closing at $31.70 after swinging between $30.76 and $34.97 on heavy volume. Options trading showed a surge in put buying, with 15,696 contracts traded, 56% above normal. The drop outpaced biotech peers as investors watched for updates on the company’s patent dispute over Yutrepia and its next earnings report, expected March 18.
2 January 2026
···
Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open

Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open

Insmed shares closed Monday at $175.76, up 0.53%, then traded between $175.76 and $178.05 after hours. The stock joined the Nasdaq-100 effective Dec. 22, prompting index-related activity. No new company announcements appeared after the bell. Investors continued to weigh last week’s brensocatib CRSsNP trial failure.
23 December 2025
··
Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025)

Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025)

Insmed joined the Nasdaq-100 Index on December 22, 2025, boosting its stock visibility. Shares traded at $177.86, up 1.7%, after recent swings triggered by a failed Phase 2b trial for brensocatib in chronic rhinosinusitis, which led the company to end that program. Insmed also acquired INS1148, a Phase 2–ready monoclonal antibody, for $40 million upfront.
22 December 2025
·
Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025)

Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025)

Insmed will join the Nasdaq-100 before markets open Monday, December 22, 2025. Shares fell 11% last week after the company halted development of brensocatib in chronic rhinosinusitis without nasal polyps following a failed Phase 2b trial. The stock last traded near $174.84. Holiday trading may affect liquidity and volatility.
21 December 2025
·
Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed shares closed at $174.84 Friday, rebounding 5% after a sharp drop triggered by its Phase 2b BiRCh trial failure in chronic rhinosinusitis without nasal polyps. The company discontinued development for that indication and announced the acquisition of a Phase 2–ready monoclonal antibody, INS1148, to expand its pipeline.
20 December 2025
··
Insmed (INSM) Stock After Hours on Dec. 19, 2025: Friday Rebound Holds, Analyst Targets Reset, and What to Watch Before the Next Market Open

Insmed (INSM) Stock After Hours on Dec. 19, 2025: Friday Rebound Holds, Analyst Targets Reset, and What to Watch Before the Next Market Open

Insmed shares closed Friday, Dec. 19, 2025, at $174.84, up nearly 5%, after a volatile week triggered by a failed Phase 2b trial for brensocatib in CRSsNP. The company said it would discontinue that program. Shares held steady in after-hours trading. Insmed also announced the acquisition of INS1148, a Phase 2–ready monoclonal antibody.
20 December 2025
·
Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next

Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next

Insmed shares rose 5% to $174.90 Friday after a steep Thursday drop, following news that its Phase 2b BiRCh trial in CRSsNP missed endpoints and the program was discontinued. Trading volume spiked Thursday as shares fell 16%. The rebound came as analysts reiterated Buy ratings, citing Insmed’s bronchiectasis franchise and respiratory pipeline. The stock remains below its 52-week high of $212.75.
19 December 2025
·
Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

Insmed shares fell 16% Thursday after the company said its Phase 2b trial of brensocatib in chronic rhinosinusitis without nasal polyps failed to meet endpoints, prompting it to end development for that indication. The drug’s performance matched or trailed placebo on symptom scores. Insmed reported no new safety issues. The stock traded near $166.75 after hitting a low of $158.06.
18 December 2025
···
Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

The FDA approved Insmed’s brensocatib as the first therapy for non-cystic fibrosis bronchiectasis, following positive results in a 1,700-patient trial. Novartis reported Phase 3 successes for ianalumab in Sjögren’s syndrome and immune thrombocytopenia. In China, RemeGen’s telitacicept met its main goal in a Phase 3 Sjögren’s trial. Response Pharmaceuticals’ RDX-002 showed weight-loss maintenance in post-GLP-1 patients.
14 August 2025
···
Tech World Rocked by 8 Non‑AI Surprises This Week

Tech World Rocked by 8 Non‑AI Surprises This Week

Apple is developing a home companion robot with a 7-inch movable display and advanced Siri, targeting a 2027 launch. The FDA approved Insmed's Brinsupri as the first treatment for non-cystic fibrosis bronchiectasis, priced at $88,000 per year. ULA's Vulcan rocket completed its first operational flight, carrying Space Force payloads from Cape Canaveral. Amazon expanded Prime same-day grocery delivery to over 1,000 U.S. cities.
14 August 2025
···········
Breakthrough Drug Approved, Billion-Dollar Deals & Outbreak Alerts – Global Biotech & Health Roundup (Aug 12–13, 2025)

Breakthrough Drug Approved, Billion-Dollar Deals & Outbreak Alerts – Global Biotech & Health Roundup (Aug 12–13, 2025)

The FDA approved brensocatib (Brinsupri) as the first treatment for non-cystic fibrosis bronchiectasis, affecting about 500,000 Americans. Novartis reported positive Phase 3 results for ianalumab in Sjögren’s syndrome and immune thrombocytopenia. Biohaven’s OCD drug troriluzole failed in late-stage trials. Cardinal Health will acquire Solaris Health for $1.9 billion in cash.
13 August 2025
···

Stock Market Today

  • TSX Rises on Middle East De-escalation; Tech Stocks Rebound in U.S.
    June 9, 2026, 12:06 AM EDT. Canada's TSX Composite Index climbed 59.57 points to 34,473.02 on Monday, buoyed by signs of easing tensions in the Middle East after Iran announced the end of its initial attacks on Israel. The materials sector led gains with significant rises in mining stocks including 5N Plus (up 4.6%). Conversely, the TSX Venture Exchange fell 1%. On Wall Street, the S&P 500 and NASDAQ recovered from last Friday's steep sell-off, with chip stocks like Micron Technology surging 10%. The Dow slipped slightly. Oil prices rose amid ongoing conflict, though U.S. President Donald Trump noted talks towards a ceasefire. Investors await key inflation data and SpaceX's public debut, a major test for AI sector valuations.

Latest articles

Chip Rally Breaks as Nasdaq Faces Tight Labor Market

Nasdaq rises after hours as chips recover

9 June 2026
Nasdaq jumped 0.86% as chip stocks rebounded, with Intel soaring 11.2% on news Google ordered over 3 million AI chips for 2028, while Apple slid 1.9% after unveiling new AI features. Investors await Wednesday’s May CPI inflation report, which could spark volatility in tech and growth stocks.
Broadcom Stock Rebounds, AI Remains an Open Question for Wall Street

Broadcom Stock Rebounds, AI Remains an Open Question for Wall Street

9 June 2026
Broadcom shares jumped 2.8% to $396.60 as chip stocks rebounded after last week’s $1 trillion sector wipeout, but investors remain cautious after Broadcom’s Q2 revenue missed expectations and the company declined to raise its 2027 AI revenue forecast, fueling concerns that rapid AI growth may not meet Wall Street’s high demands.
BitMine Stock Gains as Ether Holdings Approach 5% Target

BitMine Stock Gains as Ether Holdings Approach 5% Target

9 June 2026
BitMine Immersion Technologies shares jumped 6% after revealing ether holdings climbed to 5.54 million tokens, now 4.59% of Ethereum’s supply, with $9.6 billion in crypto, cash and stakes. The company priced a $273.8 million preferred stock offering, with proceeds possibly funding more ETH purchases and staking. BitMine projects $230 million in annualized staking revenues but warns of risks if ETH or financing falters.
Mingteng Stock Jumps 81% After Halting $100M Share Sale Plan

Mingteng Stock Jumps 81% After Halting $100M Share Sale Plan

9 June 2026
Mingteng International shares soared 81.3% to $1.94 after the company ended its at-the-market stock sale plan, having raised about $20.6 million in gross proceeds; trading volume hit 24.2 million, dwarfing its $12 million market value, as the move outpaced gains in other U.S.-listed China auto stocks.
Go toTop